Chamovision Shines at 2025 AAPOS Annual Meeting with Breakthrough Ophthalmic Innovations

In the continuous breakthroughs of medical technology, cutting-edge academic exchange platforms play a crucial role. From March 5 to 9, 2025 (U.S. local time), the 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) was grandly held in Salt Lake City, Utah, USA. As the top academic event in the global field of strabismus and pediatric ophthalmology, the AAPOS Annual Meeting attracted ophthalmology experts, scholars, and industry elites from around the world. Participants gathered here to deeply discuss cutting-edge topics in ophthalmology such as amblyopia, nystagmus, pediatric fundus diseases, and pediatric neuro-ophthalmology, collectively exploring new directions for industry development. Super Vision, invested by Reconstructive Capital and a rising force in the field of ophthalmic medical innovation, made a remarkable appearance at this annual meeting, with its innovative achievements drawing significant attention.

During the AAPOS conference, Dr. Zequn Miao from Peking University People's Hospital was invited to give a presentation titled "Single Side Stimulation of Lateral Rectus for Treating Congenital Nystagmus," sharing the breakthrough progress made by Professor Lejin Wang's team in the treatment of congenital nystagmus.

Congenital nystagmus has long been regarded as an "incurable disease" in the field of ophthalmology, with a large number of unmet clinical needs. The i-NYS implantable ocular muscle neurostimulator developed by Professor Wang Lejin's team, with its innovative integrated chip technology, provides a new solution for clinical treatment. According to the results of the i-NYS China multicenter clinical trial, i-NYS neurostimulation therapy can significantly prolong the foveal fixation time, reduce the amplitude and frequency of nystagmus, and effectively improve patients' visual quality and quality of life.

This achievement garnered widespread attention at the conference. Professor David Hunter, Vice President of AAPOS and from Boston Children's Hospital, highly praised the i-NYS technology and expressed anticipation for deeper collaboration. The American Nystagmus Network also showed strong interest in the technology and has extended an invitation to the Super Vision team to participate in the upcoming American Nystagmus Patient Conference to be held in Philadelphia.

In addition to the highly anticipated i-NYS system, Super Vision also showcased innovative products for strabismus diagnosis and treatment — i-STRA, and a precise corneal cross-linking device — i-MYO at the annual conference. These cutting-edge technologies comprehensively cover the treatment needs of various ophthalmic conditions such as strabismus, myopia, and keratoconus, fully demonstrating Super Vision's deep strategic layout and innovative strength in the field of ophthalmic healthcare.

During the exhibition, Super Vision actively exchanged ideas with global ophthalmology experts and scholars, conducting in-depth discussions on the future development direction of ophthalmic medical innovation, contributing to the advancement of the industry. Super Vision always adheres to the mission of addressing unmet clinical needs in the ophthalmology field, committed to providing global patients with higher quality and more effective treatment solutions. Rejuven Capital will continue to offer solid support to Super Vision, assisting it in steadily advancing on the path of ophthalmic medical innovation, bringing light and hope to more patients.